# Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Source: https://onco.cc/trials/nct05630209/  
OnCo record `nct05630209` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Doxorubicin in brain and spinal cord tumours, run by InSightec, active and no longer recruiting.

## Summary

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) is a phase 1/2 interventional study registered as NCT05630209 by InSightec, with 10 participants enrolled, started 2023-01-04 and due to reach its primary completion in 2026-06. Interventions recorded: Exablate and Doxorubicin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05630209
- Phase: 1/2
- Setting: A Safety and Feasibility Study to Evaluate Blood Brain Barrier Disruption Using Exablate MR Guided Focused Ultrasound in Combination With Doxorubicin in Treating Pediatric Patients With Diffuse Intrinsic Pontine Gliomas (DIPG)
- Sponsor: InSightec
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT05630209: https://clinicaltrials.gov/study/NCT05630209

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- companies: [Insightec](https://onco.cc/companies/insightec/)

---
JSON: https://onco.cc/api/v1/entities/nct05630209.json